BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 06/03/2017

Public Meeting on Patient-Focused Drug Development for Autism; Request for Comments

The Food and Drug Administration (FDA, the Agency, or we) is announcing a public meeting and an opportunity for public comment on Patient-Focused Drug Development for autism. Patient-Focused Drug Development is part of FDA's performance commitments made as part of the fifth authorization of the Prescription Drug User Fee Act (PDUFA V). The public meeting is intended to allow FDA to obtain patient perspectives on the impact of autism on daily life as well as patient views on treatment approaches for autism.

Source: Federal Register — Food and Drug AdministrationOpen original release →